雷帕霉素对（C57BL/6 小鼠）小鼠肝纤维化的有益作用。
Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse).
机构信息
Department of Biomedical Laboratory Science, Catholic Kwandong University, Gangneung, Republic of Korea.
Department of Surgery, School of Medicine, Kyung Hee University, Seoul, Republic of Korea.
出版信息
Transplant Proc. 2024 Apr;56(3):701-704. doi: 10.1016/j.transproceed.2024.03.001. Epub 2024 Mar 27.
BACKGROUND
Liver fibrosis is a chronic inflammatory disease that progresses and has a high mortality rate. This study was performed to investigate the protective effect of rapamycin on experimentally induced chronic liver injury in mice models using both biochemical parameters of liver function enzymes.
METHODS
Twenty-four mice were divided randomly into 4 equal groups: [1] the normal group, n = 6; [2] the liver fibrosis (LF) group, n = 6; [3] the LF with the treatment of rapamycin group, n = 6; [4] the LF with the treatment of silimaryn, n = 6.
RESULTS
In the group receiving oral administration of rapamycin, aspartate aminotransferase, alanine aminotransferase, urea, and creatinine were found to significantly decrease compared to the liver fibrosis group. Rapamycin, in the orally administered group, demonstrated a statistically significant decrease in the expression of interleukin (IL) 10, IL-1B, inducible nitric oxide synthase, and tumor necrosis factor alpha compared to the liver fibrosis group.
CONCLUSIONS
In this study, we explored the potential therapeutic effects of rapamycin on liver fibrosis in an animal model.
背景
肝纤维化是一种慢性炎症性疾病，进展迅速，死亡率高。本研究旨在通过肝功能酶的生化参数，探讨雷帕霉素对实验性诱导的慢性肝损伤小鼠模型的保护作用。
方法
将 24 只小鼠随机分为 4 组，每组 6 只：[1]正常组；[2]肝纤维化（LF）组；[3]LF 雷帕霉素治疗组；[4]LF 水飞蓟宾治疗组。
结果
与肝纤维化组相比，口服雷帕霉素组的天冬氨酸转氨酶、丙氨酸转氨酶、尿素和肌酐明显降低。与肝纤维化组相比，口服雷帕霉素组白细胞介素（IL）-10、IL-1B、诱导型一氧化氮合酶和肿瘤坏死因子-α的表达显著降低。
结论
在这项研究中，我们在动物模型中探索了雷帕霉素治疗肝纤维化的潜在治疗效果。
Zotero 插件